Evaluation of the clinical value of measurement of cross-linked fibrin derivatives with monoclonal antibody (IATRON)

Abstract

Plasma level of cross-linked fibrin degradation products (XDP) was measured by latex agglutination using a new monoclonal antibody against Decate (Iatron Co., Tokyo, Japan). Plasma XDP (expressed as DD/E) was undetectable (<1μg/ml) in 80 healthy subjects (mean age 43.7±19.1 years), but showed high levels in 14 of 15 patients with DIC. The levels of DD/E and total FDP measured with antibody against human fibrinogen changed in parallel with their clinical course during treatment with heparin for DIC. Furthermore, there was significant correlation between levels of DD/E and total FDP in 46 samples from patients with DIC (p<0.01). But the level of total FDP was very high in comparison with that of DD/E in a DIC patient, and in 3 patients with acute myocardial infarction during infusion of recombinant t-PA. Those results suggested that this method for XDP was sensitive and useful to assessment of fibrinolysis in circulating blood.